Registration studies — when should patients be deemed ineligible for aggressive therapy?

Registration studies — when should patients be deemed ineligible for aggressive therapy?Registration studies — when should patients be deemed ineligible for aggressive therapy?, Published online: 18 February 2019; doi:10.1038/s41571-019-0180-xThe approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.

Source: Nature Clinical Practice Oncology - February 18, 2019 Category: Cancer & Oncology Authors: Rachel J. Cook Jennifer Gill Vinay Prasad Source Type: research